Comparative lung bioavailability of fluticasone/salmeterol via breath actuated vortex spacer and conventional plastic spacers Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Effect of antistatic AeroChamber Plus® Flow-Vu® spacer on the systemic bioavailability of CHF5993 a novel triple pMDI Source: International Congress 2016 – Pulmonary drug delivery Year: 2016
Relative bioavailability of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) administered with and without a spacer in healthy adults Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019
Pharmacokinetics of tobramycin nebulizer solution (300mg/4ml) administered by Pari e-Flow rapid vs Pari LC plus nebulizer in patients with cystic fibrosis and Pseudomonas aeruginosa infection Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new aspects of risk factors, treatments and diagnosis Year: 2012
Assessment of lung deposition and pharmacokinetics in 12 lung transplanted patients after inhalation of a novel liposomal ciclosporin a (CsA) formulation by the eFlow electronic nebuliser Source: Eur Respir J 2007; 30: Suppl. 51, 29s Year: 2007
Equivalent pharmacokinetics of the active metabolite of ciclesonide when using the ciclesonide-MDI with and without a spacer Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004
Optimization of inhalation treatment – Evaluation of influence of spacer integrated with the spirometer on aerosol particle distribution from pMDI-EB Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010
In vitro aerosol delivery by vibrating mesh nebulizer (VMN) and pressurized metered dose inhaler (pMDI) using spacers in comparison with T adapters in mechanical ventilation. Source: Respiratory Failure and Mechanical Ventilation Conference 2020 Year: 2020
Effect of device and formulation on delivery of budesonide suspensions by nebulizers Source: Eur Respir J 2002; 20: Suppl. 38, 542s Year: 2002
Urinary pharmacokinetic method to identify the relative bioavailability of beclometasone dipropionate (BDP) to the lung and body following inhalation Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010
Aerosol characterization of three corticosteroids in MDIs plus a new spacer device (Fluspacer®) vs MDIs alone Source: Eur Respir J 2001; 18: Suppl. 33, 101s Year: 2001
Effect of the actuator orifice diameter on the biodisposition of a new budesonide CFC-free metered dose inhaler formulation Source: Eur Respir J 2001; 18: Suppl. 33, 102s Year: 2001
Characterization of the performance of a new portable jet nebulizer system for the delivery of budesonide suspension for nebulization Source: Annual Congress 2008 - Wheezing in preschool children Year: 2008
Validation of monodisperse corticosteroid aerosols for in-vivo delivery Source: Annual Congress 2008 - Investigation, inspiration, ventilation, dedication: the essence of physiological measurement Year: 2008
Comparison of the pharmacokinetic, pharmacodynamic, and safety profiles of three different formulations of intravenous epoprostenol sodium Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012
The in vitro fine particle dose with Symbicort Rapihaler pMDI is similar using either NebuChamber or AeroChamber Plus valved holding chamber spacer devices Source: Eur Respir J 2005; 26: Suppl. 49, 504s Year: 2005
Clinical pharmacokinetic (PK) performance of a ralinepag extended-release (XR) tablet Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018
A novel breath-actuated vortex spacer device increases respirable dose delivery of fluticasone/salmeterol in combination Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008
Lung targeting of flunisolide is enhanced when delivered as an extra fine HFA aerosol with a built-in spacer Source: Eur Respir J 2001; 18: Suppl. 33, 70s Year: 2001
Efficacy and safety of nebulized glycopyrrolate (EP-101) for administration using high efficiency nebulizer in patients with COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011